# A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

> **NCT00128830** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 211 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1

## Interventions

- **DRUG:** Etravirine (ETR)
- **DRUG:** Nucleotide reverse transcriptase inhibitors (NRTIs)
- **DRUG:** Protease inhibitors (PIs)
- **DRUG:** Enfuvirtide (ENF)

## Key facts

- **NCT ID:** NCT00128830
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128830, "A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00128830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*